このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

General Biologicals マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

T.C. Lin

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

Feb 05

CEO（最高経営責任者

T.C. Lin

no data

在職期間

Mr. T.C. Lin serves as Chairman and Chief Executive Officer at General Biologicals Corporation.

General Biologicals マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Less than half of directors are independent

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

Recent updates

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$0.89 loss in FY 2022)

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

New minor risk - Financial data availability

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: NT$0.74 (vs NT$1.18 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS NT$0.88 (vs NT$0.053 loss in 1H 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.18 (vs NT$0.99 loss in FY 2019)

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

New 90-day low: NT$43.00

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

New 90-day low: NT$44.00

New 90-day low: NT$55.60

General Biologicals Corporation (GTSM:4117) completed the acquisition of additional 77% stake in Pacgen Life Science Corporation (TSXV:PBS).

New 90-day low: NT$70.50

New 90-day low - NT$99.00

First half earnings released

General Biologicals Corporation announced that it has received TWD 77.623729 million in funding from Hong Kong Chlitina International Limited

CEO（最高経営責任者

在職期間

General Biologicals マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Less than half of directors are independent

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

Recent updates

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$0.89 loss in FY 2022)

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

New minor risk - Financial data availability

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: NT$0.74 (vs NT$1.18 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS NT$0.88 (vs NT$0.053 loss in 1H 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.18 (vs NT$0.99 loss in FY 2019)

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

New 90-day low: NT$43.00

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

New 90-day low: NT$44.00

New 90-day low: NT$55.60

General Biologicals Corporation (GTSM:4117) completed the acquisition of additional 77% stake in Pacgen Life Science Corporation (TSXV:PBS).

New 90-day low: NT$70.50

New 90-day low - NT$99.00

First half earnings released

General Biologicals Corporation announced that it has received TWD 77.623729 million in funding from Hong Kong Chlitina International Limited

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04